FOXK2 and metastatic melanoma: In the metastatic melanoma immune therapy cohort study by Ulloa‐Montoya et al.22(GSE35640), patients with higher levels of FOXK2 expression showed poorer immunotherapy response compared to those with lower expression levels (Wilcoxon test, p < 0.05) (Figure 4a,b).